Tag: GEN inCode

GEN inCode Announces Major UK Collaboration With Royal Brompton and Harefield Hospitals

OXFORD, England, April 28, 2021 /PRNewswire/ — GEN inCode UK Limited, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, announces today a collaboration with Royal Brompton and Harefield hospitals (“RB&H”), recently merged with Guy’s and St Thomas’ NHS Foundation Trust (“GSTT”), to provide globally leading cardiovascular disease clinical genetic […]

GEN inCode Appoints New Chairman

OXFORD, England, Jan. 7, 2021 /PRNewswire/ — GEN inCode UK Limited the privately-owned artificial intelligence cardiovascular disease company focused on the prevention of cardiovascular disease, announces today the appointment of Bill Rhodes as non-executive Chairman of the Company, effective 1 January, 2021. Bill Rhodes is a Chairman with a proven, demonstrable international track record in the Life Sciences […]

GEN inCode Appoints Chief Financial Officer

OXFORD, England, Dec. 7, 2020 /PRNewswire/ — GEN inCode UK Limited the privately-owned artificial intelligence cardiovascular disease company focused on the prevention of cardiovascular disease announces today the appointment of Paul Foulger as Chief Financial Officer to the Company. Paul Foulger is an experienced CFO with a proven, demonstrable track record in the Biotech industry for both […]

GEN inCode Announces Completion of £3M Institutional Foundation Fundraise

OXFORD, England, Sept. 1, 2020 /PRNewswire/ — GEN inCode UK Limited, the privately-owned artificial intelligence cardiovascular disease company focused on the prevention of cardiovascular disease, announces today the completion of a £3.0M institutional fundraise to internationally scale its products and technology. GEN inCode specializes in genetic risk assessment and the prediction of cardiovascular […]